CervoMed Announces Completion of Merger with EIP Pharma

CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, has announced the closing of its previously announced merger with EIP Pharma Inc. The combined company will operate under the name CervoMed Inc., and its shares will commence trading on a 1-for-1.5 reverse split adjusted basis on August 17, 2023, on the Nasdaq Capital Market under the ticker symbol “CRVO”. CervoMed’s focus will be on advancing its lead drug candidate neflamapimod, an oral stress kinase inhibitor, which is currently being developed for the treatment of dementia with Lewy bodies (DLB) and other degenerative diseases of the brain.

Read the full article: CervoMed Announces Completion of Merger with EIP Pharma //

Source: https://www.prnewswire.com/news-releases/cervomed-announces-completion-of-merger-with-eip-pharma-301902808.html

Leave a Comment

Your email address will not be published.

Scroll to Top